[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"wound\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:wound":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,11,0,[8,40,68,90,118,146,169,204,229,254,280],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":34,"leadSponsor":36,"locationsCount":39},"100636365","study-of-tolerance-to-the-application-of-cold-plasma-in-the-treatment-of-chronic-wounds-100636365",false,"NCT07564739","Study of Tolerance to the Application of Cold Plasma in the Treatment of Chronic Wounds","PLASMA-SAFE","Inclusion Criteria:\n\n1. Men or women.\n2. Aged 18 years or older.\n3. Chronic wound or ulceration.\n4. Wound measuring 5 to 100 cm² of arterial or venous origin.\n5. Evolution \\> 4 weeks.\n6. With less than 30% necrosis.\n7. Able to give informed written consent.\n8. Blood pregnancy test for women of childbearing age.\n\nExclusion Criteria:\n\n1. Tumor wounds\n2. Dialysis\n3. Patients requiring surgical revascularization\n4. Severe heart failure (NYHA III-IV) or acute myocardial infarction.\n5. Wounds or ulcers located less than 10 cm from the patient's airways and respiratory tract\n6. Severe renal failure defined as creatinine clearance \\\u003C20 mL\u002Fmin calculated according to the MDRD\n7. Patients with severe hepatic impairment (class C) according to the Child Pugh score\n8. Unstable liver disease (defined by the presence of ascites, encephalopathy, coagulopathy, hypoalbuminemia, esophageal or gastric varices, or persistent jaundice), cirrhosis, known biliary abnormality.\n9. Active malignant tumor\n10. Patients who, in the investigator's opinion, are at significant risk of suicide\n11. Any pre-existing physical or mental condition that may interfere with the patient's ability to comply with the administration schedule and\u002For protocol assessments, or that may compromise the patient's safety.\n12. Persons covered by Articles L.1121-5 to L.1121-8 and L.1122-1-2 of the Public Health Code (including minors and protected adults)\n13. Protected person (under guardianship or curatorship)\n14. Person under judicial protection\n15. Persons deprived of their liberty\n16. Persons not affiliated with a social security system\n17. Women who are pregnant or breastfeeding, or who plan to become pregnant or breastfeed during the study.\n18. Patients participating in another clinical trial evaluating a treatment\n19. Allergy to the dressings used in the trial","ALL","18 Years",{"count":19,"type":20},40,"ESTIMATED","INTERVENTIONAL",[23],"NA","Chronic wounds affect many patients, with no downward trend in recent decades. This is a significant economic and social issue, and this condition has an impact on functional disabilities and quality of life, especially among the elderly. Diagnosis is essentially clinical, and there are many causes, but 90% of leg ulcers, for example, are primarily vascular in origin. There are wounds of traumatic, post-operative, and vascular origin, as well as pressure sores. The main purpose of invasive tests is to objectively determine the cause (arterial damage) or to check for underlying osteitis. Chronic wounds are usually infected or colonized by bacteria from the skin and digestive flora. There is no indication for antibiotic therapy in the treatment of wounds. Nursing staff play an important role in therapeutic management, which must be carried out in harmony with other healthcare professionals, such as general practitioners and specialists. This management has two main goals: to accelerate the epidermalization of chronic wounds, or even their healing, and to limit local and general complications, the recurrence of which remains the most difficult to control. There are many types of healing dressings available, adapted to each type of ulceration: fibrinous, necrotic, superinfected, etc.\n\nNevertheless, innovative solutions can accelerate healing, thereby reducing hospital stays, disabilities associated with chronic wounds, and complications such as skin-related septicemia. Research efforts may focus on the use of growth factors, for example, for old or stubborn forms of the disease, despite proper medical treatment, or on any other innovative technique.\n\nThe properties of cold plasma appear to be suitable for the treatment of chronic wounds, as has been demonstrated in cell models, animal models, and with argon plasma in several countries around the world on an experimental basis in humans.\n\nThe GREMI in Orléans has acquired internationally recognized expertise in the technique of cold helium plasma. The combination of this applied research laboratory and the Infectious Diseases Department of the Orléans University Hospital has led to the development of relationships that have resulted in the proposal to conduct this study, based in its first phase on the evaluation of the medical device's tolerance.",[26,27],"Wound","Chronic Ulcer","RECRUITING","2026-05-12",{"date":31,"type":32},"2026-05-15","ACTUAL",{"date":29,"type":32},{"date":35,"type":20},"2027-09",{"name":37,"class":38},"Centre Hospitalier Régional d'Orléans","OTHER",1,{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":4,"eligibilityCriteria":46,"healthyVolunteers":47,"sex":16,"minAge":48,"maxAge":4,"enrollmentInfo":49,"targetDuration":4,"studyType":21,"phases":51,"briefSummary":52,"conditions":53,"keywords":54,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":57,"lastUpdatePostDateStruct":58,"startDateStruct":60,"completionDateStruct":62,"leadSponsor":64,"locationsCount":67},"100564147","a-study-evaluating-the-safety-and-efficacy-of-the-3m-vac-peel-and-place-dressing-100564147","NCT06625385","A Study Evaluating the Safety and Efficacy of the 3M™ V.A.C. Peel and Place Dressing","A Post-market, Prospective, Multi-center, Single-arm Study Evaluating the Safety and Efficacy of the 3M™ V.A.C. Peel and Place Dressing Used in Conjunction With 3M™ V.A.C.® Therapy","Inclusion Criteria:\n\n1. Subject is at least 22 years old at the time of consent.\n2. Subject or legally authorized representative (LAR) is able to provide informed consent.\n3. Subject has a wound deemed appropriate for treatment with a V.A.C.® Peel and Place dressing (used in conjunction with 3M™ V.A.C.® Therapy), according to the instructions for use for the dressing, including the following wound types:\n\n   * an open wound: traumatic wound, dehisced surgical wound within 30 days of surgery, burn, venous ulcer, diabetic ulcer, or pressure ulcer Note: Prior to initial placement, the wound may be debrided, as clinically indicated\n   * a closed or covered wound secured with sutures or staples: closed surgical incision, skin flap closure, or skin graft (recipient site)\n4. Subject is willing and able to attend all study visits.\n\nExclusion Criteria:\n\n1. Subject is pregnant or lactating prior to application of the initial dressing. \\*\n\n   \\*Women who have had surgical sterilization by a medically accepted method (ie, tubal ligation, hysterectomy, or oophorectomy) or are post-menopausal, defined as not having menstruation for \\> 12 months will not be required to undergo pregnancy testing.\n2. Subject is participating in another interventional clinical study or was enrolled in a clinical trial within the last 30 days before screening.\n3. Subject has been diagnosed with a malignancy in the wound.\n4. Subject has untreated osteomyelitis or untreated cellulitis in the wound.\n5. Subject has an untreated systemic infection.\n6. Subject has active cellulitis in the peri-wound area.\n7. Subject has a known allergy or hypersensitivity to study materials: dressing(s), and\u002For dressing components such as acrylic or silicone adhesives or polyurethane.\n8. Subject has, in the opinion of the investigator, a clinically significant condition that would impair the Subject's ability to comply with the study procedures or would compromise assessment of endpoints (wound\u002Fperi-wound condition).\n9. Subject has had radiation directly to the wound area.\n10. Subject received hyperbaric oxygen therapy within 30 days before the initial application of a V.A.C.® Peel and Place dressing.\n11. Subject has been diagnosed with a major vascular deficit limiting arterial inflow into the wound region, as determined by the investigator's interpretation of the subject's medical history.\n12. In the case of a lower extremity wound, the Subject has one of the following:\n\n    * an ankle brachial index \\\u003C 0.8;\n    * no palpable pulse; or\n    * no discernable audio Doppler signal.\n\nIndividual wounds are to be excluded from the study if they meet any of the following criteria\n\n1. Wound has necrotic tissue and\u002For eschar present. NOTE: After debridement of necrotic tissue and complete removal of eschar, the V.A.C.® Peel and Place dressings may be used.\n2. Wound contains a non-enteric or unexplored fistula(s) in the wound bed.\n3. Wound has tunneling.\n4. Wound has undermining that is ≥ 2 cm in any direction from the wound edge.\n5. Wound site has inadequate hemostasis, as determined by the investigator.\n6. Wound has exposed vessels, anastomotic sites, organs, or nerves that cannot be protected prior to placement of the V.A.C.® Peel and Place Dressings.\n7. Wound has a depth greater than 2 cm (for small dressings), 4 cm (for medium dressing size), or 6 cm (for the large dressing size).\n8. The wound received, within 30 days before initiating V.A.C.® Therapy, treatment with any of the following:\n\n   * any previous negative pressure wound therapy device.\n   * growth factors.\n   * bioengineered tissue products, eg, skin or dermal substitutes.\n9. Wound was closed with tissue adhesive.\n10. Wound has, in the opinion of the Investigator, any characteristic that would make it unsuitable for the study.",true,"22 Years",{"count":50,"type":20},90,[23],"The purpose of this clinical study is to obtain post-market safety and efficacy data when the V.A.C.® Peel and Place dressing is used in conjunction with 3M™ V.A.C.® Therapy.",[26],[55,56],"Open","Closed","2026-02-11",{"date":59,"type":32},"2026-02-13",{"date":61,"type":32},"2025-01-20",{"date":63,"type":20},"2027-05",{"name":65,"class":66},"Solventum US LLC","INDUSTRY",3,{"id":69,"slug":70,"hasResults":11,"nctId":71,"briefTitle":72,"officialTitle":73,"acronym":4,"eligibilityCriteria":74,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":75,"enrollmentInfo":76,"targetDuration":4,"studyType":21,"phases":78,"briefSummary":79,"conditions":80,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":82,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":88,"locationsCount":39},"100619629","miro3d-randomized-controlled-trial-rct-100619629","NCT07347106","Miro3D Randomized Controlled Trial (RCT)","A Prospective, Randomized Controlled Trial of Miro3D Wound Matrix With Standard of Care Versus Standard of Care Alone in Treating Acute Soft Tissue Wounds and Chronic Pressure Ulcerations","Inclusion Criteria:\n\n* Subjects must fulfill all the following inclusion criteria to qualify for enrollment:\n\n  1. Men or women 18-90 years of age at enrollment.\n  2. Ability to sign consent by subject or LAR.\n  3. Wounds in one of the two arms:\n\n     * A. Soft tissue wounds with a minimum size of 1 cm x 1 cm surface area and a maximum size of 40 cm L x 20 cm W x 5 cm D, resulting from either post-fasciotomy or post-NSSTI, including the pelvis with the lower extremity. Fasciotomies must have undergone complete debridement and, in the opinion of a trial investigator, be appropriate for wound healing but not ready for primary closure at randomization.\n     * B. Chronic, complex pressure ulcers classified as Stage III or higher, located in the decubitus or ischial region, that have not achieved at least a 50% reduction in ulcer area despite receiving documented SOC treatment for a minimum of four (4) weeks, with confirmed patient compliance.\n  4. Subjects must agree to proper offloading and\u002For compression of the wound or ulcer throughout the trial.\n  5. Written informed consent is required for digital photo imaging.\n  6. For the Miro3D plus SOC arm, the wound or ulcer must have a clean base that is free of devitalized tissue or debris at the time of Miro3D placement.\n  7. Subjects receiving NPWT at baseline are eligible for enrollment. The use of NPWT during the trial will be at the discretion of the treating provider.\n\nExclusion Criteria:\n\n* Subjects who meet any of the following criteria will be excluded from trial participation:\n\n  1. The PAR of the pressure ulcer arm has reduced by 50% or more after four (4) weeks of SOC.\n  2. Wounds with active invasive infection not yet controlled in the opinion of a trial investigator.\n  3. Wounds with vascular insufficiencies requiring revascularization.\n  4. Trial investigator deems the subject has no meaningful wound healing potential (e.g., advanced cancer, severe malnutrition) and\u002For has conditions that seriously compromise the subject's ability to complete the trial or a known history of non-adherence to medical care.\n  5. Undergoing chemotherapy.\n  6. History of radiation to the area of the index wound or ulcer, regardless of time since last radiation treatment.\n  7. Use of investigational drugs or therapies within thirty (30) days before screening.\n  8. On dialysis.\n  9. Sensitivity, allergy, or contraindication to Miro3D and\u002For NPWT or its components.\n  10. Presence of third-degree burns.\n  11. Index wound or ulcer exhibiting worsening ischemia or gangrene at screening.\n  12. Subjects moving toward palliative or comfort care.","90 Years",{"count":77,"type":20},70,[23],"The purpose of this research study is to evaluate the outcomes for patients managed with standard of care (SOC) wound treatments and those managed with standard of care treatment and tissue scaffolds, specifically Miro 3D. Tissue scaffolds like Miro 3D are 3-dimentional frameworks for collagen protein that provide structure and protection to help wounds heal.",[26],"2026-01-15",{"date":83,"type":32},"2026-01-20",{"date":85,"type":20},"2026-01",{"date":87,"type":20},"2028-07",{"name":89,"class":38},"Washington University School of Medicine",{"id":91,"slug":92,"hasResults":11,"nctId":93,"briefTitle":94,"officialTitle":95,"acronym":4,"eligibilityCriteria":96,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":97,"targetDuration":4,"studyType":21,"phases":99,"briefSummary":101,"conditions":102,"keywords":106,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":108,"lastUpdatePostDateStruct":109,"startDateStruct":111,"completionDateStruct":113,"leadSponsor":115,"locationsCount":117},"100510728","phase-3-a-study-to-evaluate-energi-f703-gel-in-diabetic-foot-ulcer-100510728","NCT05930210","A Study to Evaluate ENERGI-F703 GEL in Diabetic Foot Ulcer","A Randomized, Double-Blind, Vehicle-controlled, Parallel, Phase III Study to Evaluate Efficacy and Safety of ENERGI-F703 GEL in Subjects With Diabetic Foot Ulcers","Inclusion Criteria:\n\n1. Subject must be at least 18 years old.\n2. Subject must have diagnosed with diabetes mellitus (DM), eg, currently under DM medication treatment or subjects with naïve DM with duplicated hemoglobin A1c over 6.5% and fasting plasma glucose over 126 mg\u002FdL measured at least 1 week apart before screening.\n3. Subject must have at least 1 cutaneous ulcer on the foot and not healing for at least 4 weeks. The largest diabetic foot ulcer will be selected as target ulcer. If 2 or more ulcers have the largest size, the one with worst grade will be selected. If 2 or more ulcers have the largest size and grade, the one with longest duration will be selected.\n4. The target ulcer is classified as Grade 1 to Grade 2 ulcer according to Wagner Grading System and with ulcer size of 1.5 cm2 to 25 cm2.\n5. Diabetic foot ulcers should be free of any necrosis or infection\n6. Subject has signed the written informed consent form\n7. Male subjects must be surgically sterile or commit to the use of a reliable method of birth control (must agree to use double-barrier contraception in the event of sexual activity) or be practicing abstinence for the duration of the study and for 30 days after study treatment administration.\n8. Female subjects are eligible only if all of the following apply:\n\n   * Not pregnant with a negative serum pregnancy test at Screening visit and negative urine pregnancy test within 24 hours before randomization (test not required for females of non-childbearing potential, defined as surgically sterile \\[eg, hysterectomy or bilateral oophorectomy\\] or postmenopausal \\[amenorrheic for at least 1 year\\])\n   * Not lactating\n   * Not planning to become pregnant during the study\n   * If of childbearing potential, commits to the use of a highly effective method of contraception for the duration of the study and at least 30 days after study treatment administration.\n\nExclusion Criteria:\n\n1. History or evidence of osteomyelitis as confirmed by the investigator. An x-ray\u002Fpathology assessment of debridement or a probe-to-bone (PTB) test will be used to determine presence of osteomyelitis. However, participants who have a history or evidence of osteomyelitis in other parts of their body are eligible to participate in the study. If the medical history of osteomyelitis was cured by antibiotic therapy, surgery or amputation for more than 1 year, and no recurrence, no finding to the current leg and foot after testing, the participant can be enrolled\n2. With target ulcer size decreased by at least 30% after at least 2 weeks of standard of care-only period between screening and randomization\n3. Subjects with highly exudated wounds which require dressing changes more than 3 times a day may be enrolled, but heavily exudated wounds should not be selected as target ulcers\n4. With poor nutritional status (serum albumin \\\u003C2g\u002FdL or prealbumin \\\u003C10 mg\u002FdL), poor diabetic control (hemoglobin A1c \\>12%), a leukocyte counts \\\u003C2,000\u002Fmm3, abnormal liver function (aspartate aminotransferase, alanine aminotransferase \\>3 x upper limit of normal range) within 21 days before Randomization visit\n5. Requiring treatment with systemic corticosteroids, immunosuppressive or chemotherapeutic agents\n6. With known or suspected hypersensitivity to any ingredients of study product and vehicle\n7. With coronary heart disease with myocardial infarction, coronary artery bypass graft, or percutaneous transluminal coronary angioplasty within 3 months prior to study (patients who have undergone peripheral angioplasty should be excluded unless the surgery was performed at least 30 days prior to screening)\n8. Known or suspected history of drug abuse or a recent history of alcohol abuse (regularly drinks \\>4 units of alcohol per day: 1 unit = 8 oz. beer, 3 oz. wine, or 1 oz. spirits) within 6 months prior to screening (within 6 months prior to screening includes both drug abuse and alcohol abuse)\n9. History or positive test results for HIV\n10. Malignancy in the last 2 years, with the exception of non-metastatic basal cell or squamous cell carcinoma of the skin or localized carcinoma in situ of the cervix\n11. Ankle brachial index \\\u003C0.8 or \\>1.4\n12. Enrollment in any investigational drug trial within 4 weeks before entering this study\n13. With any condition judged by the investigator that entering the trial may be detrimental to the subject -",{"count":98,"type":20},230,[100],"PHASE3","This Phase 3 study is a randomized, double-blind, vehicle-controlled, multiple-center, parallel study to evaluate efficacy and safety of ENERGI-F703 GEL compared with vehicle control in subjects with Wagner Grade 1 to Grade 2 diabetic foot ulcers. Baseline target ulcer size (\\\u003C16 cm2 vs ≥16 cm2 ) will be included as a stratification factor. Subjects will be randomized 1:1 to receive ENERGI-F703 GEL or vehicle control using an interactive web response system for randomization to automatically assign a unique subject randomization number. Total duration of the study will be up to 31 weeks including Screening visit (approximately 2 to 3 weeks), double-blind dosing\u002Fobservation phase (16 weeks), and a safety follow-up of 12 weeks after the last administration of study treatment.",[103,104,105,26],"Diabetic Foot Ulcer","Foot Ulcer","Diabetes Mellitus",[103,105,107],"Wound Healing","2025-09-29",{"date":110,"type":32},"2025-10-02",{"date":112,"type":32},"2023-05-30",{"date":114,"type":20},"2026-03-31",{"name":116,"class":66},"Energenesis Biomedical Co., Ltd.",24,{"id":119,"slug":120,"hasResults":11,"nctId":121,"briefTitle":122,"officialTitle":122,"acronym":4,"eligibilityCriteria":123,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":124,"enrollmentInfo":125,"targetDuration":4,"studyType":21,"phases":127,"briefSummary":128,"conditions":129,"keywords":132,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":137,"lastUpdatePostDateStruct":138,"startDateStruct":140,"completionDateStruct":142,"leadSponsor":144,"locationsCount":39},"100577694","phase-3-novel-strategies-for-reducing-burn-scar-itch-100577694","NCT06801626","Novel Strategies for Reducing Burn Scar Itch","Inclusion Criteria:\n\nParticipants must meet all the inclusion criteria in order to be eligible to participate in the study.\n\n* Participant has provided informed consent in a manner approved by the IRB and is willing and able to comply with the trial procedures.\n* Adults: ≥18 to \\\u003C80 years of age.\n* Has an itchy burn scar.\n\nExclusion Criteria:\n\nParticipants meeting any of the exclusion criteria at baseline will be excluded from study participation.\n\n* Failure to obtain consent or unable to return for follow up assessments.\n* Patient is unable to follow the protocol required assessments.\n* Member of a vulnerable class (e.g., prisoners, pregnant participant, etc.).\n* Any medical condition that, in the opinion of the investigator or physician, would place the participant at increased risk for participation.\n* Concurrent participation in another interventional clinical trial (to avoid confounding factors that may influence outcomes).\n* History of prior non-compliance or the presence or history of psychiatric condition (including drug or alcohol addiction) that would, in the opinion of the investigator, make it difficult for the participant to comply with the study procedures or follow the investigators instructions.\n* Age \\\u003C 18 or ≥ 80 years.\n* Taking one of the following medications: cefuroxime, dasatinib, delavirdine, neratinib, pazopanib, risedronate, or tizanidine.\n* Has a pre-existing inflammatory or itchy skin disease.\n* Is taking an H2 antihistamine for another indication.","80 Years",{"count":126,"type":20},44,[100],"The purpose of the study is to see whether using diphenhydramine (Benadryl), famotidine (Pepcid), and cromolyn sodium will decrease burn scar itch.",[130,131,26],"Burn Scar","Itch Scarring",[133,134,135,136],"Itch","Burn","Diphenhydramine","Famotidine","2025-09-18",{"date":139,"type":32},"2025-09-24",{"date":141,"type":32},"2025-03-01",{"date":143,"type":20},"2027-11-01",{"name":145,"class":38},"The University of Texas Medical Branch, Galveston",{"id":147,"slug":148,"hasResults":11,"nctId":149,"briefTitle":150,"officialTitle":150,"acronym":4,"eligibilityCriteria":151,"healthyVolunteers":11,"sex":16,"minAge":152,"maxAge":153,"enrollmentInfo":154,"targetDuration":4,"studyType":21,"phases":155,"briefSummary":156,"conditions":157,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":160,"lastUpdatePostDateStruct":161,"startDateStruct":163,"completionDateStruct":165,"leadSponsor":167,"locationsCount":39},"100589711","prophylactic-negative-pressure-wound-therapy-in-laparotomy-wounds-a-randomized-clinical-trial-100589711","NCT06957964","Prophylactic Negative Pressure Wound Therapy in Laparotomy Wounds: A Randomized Clinical Trial","Inclusion Criteria:\n\n* Patients of age between 20 to 70 years, both genders\n* Undergoing laparotomy under general anaesthesia\n* ASA I-II\n\nExclusion Criteria:\n\n* Patients who did not complete the follow up instructions\n* Pregnant patients\n* Patients already undergone a relook laparotomy, if their abdomen is left open or if unable to adhere","20 Years","70 Years",{"count":77,"type":20},[23],"Total 70 participants meeting selection criteria will be enrolled in the study from operational theatre. They will be randomly divided in two groups by using lottery method. In group A, Negative Pressure Wound Therapy will be applied at end of procedure. In group B, no Negative Pressure Wound Therapy will be placed. They will be shifted to post-surgical wad for 72 hours and then will be discharged with prescription of standard antibiotics and will be followed-up in OPD for 30 days. If patient will develop surgical site wound infection, then it will be noted. If infection will not be cured with antibiotics course, then re-operation will be done. Patients complications will be managed as per hospital protocol. All this information will be recorded in proforma.",[26,158,159],"Infection Prevention","Negative Pressure Wound Therapy","2025-04-27",{"date":162,"type":32},"2025-05-06",{"date":164,"type":32},"2025-03-25",{"date":166,"type":20},"2025-06-25",{"name":168,"class":38},"Dr Hamail Khanum",{"id":170,"slug":171,"hasResults":11,"nctId":172,"briefTitle":173,"officialTitle":174,"acronym":175,"eligibilityCriteria":176,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":177,"targetDuration":4,"studyType":21,"phases":179,"briefSummary":180,"conditions":181,"keywords":189,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":195,"lastUpdatePostDateStruct":196,"startDateStruct":198,"completionDateStruct":200,"leadSponsor":202,"locationsCount":203},"100570427","phase-3-tissue-repair-gel-in-venous-leg-ulcers-in-auus-100570427","NCT06707103","Tissue Repair Gel in Venous Leg Ulcers in AU\u002FUS","A Phase 3 Randomized, Parallel Group, Double-Blind Study to Evaluate the Efficacy, Tolerability, and Safety of TR987® 0.1% Gel Versus Standard of Care in the Treatment of Chronic Venous Insufficiency Leg Ulcers (VLU)","TRIVIA","Inclusion Criteria:\n\n* Adults 18 years and older\n* Venous insufficiency has been clinically diagnosed clinically and medically confirmed.\n* Females who are neither pregnant nor breastfeeding and if of child-bearing potential are on an acceptable method of birth control.\n* The Venous Ulcer should be between 2 cm2 and 12 cm2 at randomization.\n* Target ulcer age must be ≥ 4 weeks at Screening.\n* Participants must have adequate arterial flow as confirmed by ABI\u002FTBI, TB, SPP, TCPo2, or Duplex Doppler.\n* Body mass index (BMI) ≤ 50 kg\u002Fm2.\n* HbA1C ≤12%.\n\nExclusion Criteria:\n\n* Target ulcer has been treated with prohibited medications or therapies.\n* History of radiation at the target ulcer site.\n* Target ulcer decreases in area by 30% or more during screening period.\n* History of osteomyelitis at the target ulcer within 6 months of screening.\n* History of cancer in the preceding 5 years (except as noted in the protocol).\n* Participants considered nutritionally deficient.",{"count":178,"type":20},312,[100],"The goal of this clinical trial is to learn if TR987 0.1% gel + Standard of Care works better than Standard of Care alone to treat Venous Leg Ulcers (VLUs). It will also provide additional information about the safety of drug TR987 0.1% gel.",[182,183,184,185,186,26,187,188],"Venous Leg Ulcer","Venous Ulcer","Venous Stasis Ulcer","Venous Stasis","Wound Heal","Venous Insufficiency of Leg","Non-healing Wound",[190,191,192,193,194],"Tissue Repair","Glucoprime","TR Therapeutics","Debridement","VLU","2025-03-27",{"date":197,"type":32},"2025-04-02",{"date":199,"type":20},"2025-04",{"date":201,"type":20},"2027-02",{"name":192,"class":66},12,{"id":205,"slug":206,"hasResults":11,"nctId":207,"briefTitle":208,"officialTitle":209,"acronym":4,"eligibilityCriteria":210,"healthyVolunteers":11,"sex":16,"minAge":152,"maxAge":4,"enrollmentInfo":211,"targetDuration":4,"studyType":21,"phases":213,"briefSummary":215,"conditions":216,"keywords":220,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":221,"lastUpdatePostDateStruct":222,"startDateStruct":224,"completionDateStruct":226,"leadSponsor":227,"locationsCount":39},"100583604","phase-4-effect-of-blood-flow-by-botulinum-toxin-injection-for-severe-peripheral-artery-occlusive-disease-100583604","NCT06878482","Effect of Blood Flow by Botulinum Toxin Injection for Severe Peripheral Artery Occlusive Disease","Effect of Increasing Blood Flow by Botulinum Toxin Local Injection for Severe Peripheral Artery Occlusive Disease: Preliminary Report","Inclusion Criteria:\n\n1. Age ≥ 20 years old\n2. Patients who have a lower extremity wound among those who have been diagnosed with moderate or severe lower extremity ischemia\n3. Patients who are unable to perform additional procedures (angioplasty, etc.) by performing peripheral vascular examination and CT angiography\n4. Wound size ≥ 1x1cm2 to ≤ 3x3cm2\n5. Patients who can follow the clinical trial procedure well and abide by the visit schedule\n6. Written informed consent to participate in the study after having fully understood the contents of the protocol and restrictions.\n\nExclusion Criteria:\n\n1. Patients with diseases that can affect neuromuscular function, such as myasthenia gravis, Eaton-Lamberton syndrome, amyotrophic lateral sclerosis, and motor neuropathy\n2. Within 4 weeks before screening, aminoglycoside antibiotics, curare-like agents, or drugs that inhibit neuromuscular function (muscle relaxants, anticholinergics, benzodiazepines, benzamides, tetracyclines, Rinco Those who have taken mycin antibiotics, etc.)\n3. Those taking aspirin, NSAIDs or anticoagulants within 7 days before screening\n4. Those who have received botulinum toxin preparations within 3 months before screening\n5. Angiography or CT angiography If one or more of the three major blood vessels in the lower extremity are open\n6. Cases in which blood flow to the lower extremities can be preserved by performing balloon angioplasty even if all three major blood vessels in the lower extremity are blocked\n7. Those who are currently taking steroids or immunosuppressants that affect wounds, or those who have taken them within one month of screening\n8. Those who have applied injection drugs or wound coverings that help improve wounds within 1 week of screening\n9. Women who are pregnant, lactating, planning to become pregnant during the clinical period, or women of childbearing age who are not using available contraceptive methods (women of childbearing age must be negative in the pregnancy test prior to injection).\n10. Those who are allergic or sensitive to botulinum toxin\n11. Those who have participated in another clinical trial within 30 days before screening or those who have not passed the half-life of the investigational product of the clinical trial that they participated in, whichever is longer.\n12. Those who are not suitable for this clinical trial under the judgment of other investigators",{"count":212,"type":20},15,[214],"PHASE4","The purpose of this study is to investigate the effect of subcutaneous injection of botulinum toxin A on wound healing caused by lower extremity ischemia.",[217,26,218,219],"Chronic Ulcer of Lower Extremity","Botulinum Toxins, Type A","Blood Circulation",[218,26,217,219],"2025-03-11",{"date":223,"type":32},"2025-03-17",{"date":225,"type":32},"2023-04-17",{"date":114,"type":20},{"name":228,"class":38},"Yonsei University",{"id":230,"slug":231,"hasResults":11,"nctId":232,"briefTitle":233,"officialTitle":234,"acronym":4,"eligibilityCriteria":235,"healthyVolunteers":11,"sex":16,"minAge":236,"maxAge":4,"enrollmentInfo":237,"targetDuration":4,"studyType":21,"phases":238,"briefSummary":239,"conditions":240,"keywords":243,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":245,"lastUpdatePostDateStruct":246,"startDateStruct":248,"completionDateStruct":250,"leadSponsor":252,"locationsCount":39},"100368594","oasis-donor-site-wounds-post-market-study-100368594","NCT04079348","Oasis Donor Site Wounds Post-Market Study","Feasibility Study to Compare OASIS Extracellular Matrix to Standard Wound Care for Treatment of Donor Site Wounds","Inclusion Criteria:\n\n1. Has a split thickness skin graft (STSG) donor site wound no greater than 14 x 20 cm in size requiring placement of a covering material.\n2. Has at least 24 hours to consent to study participation.\n\nExclusion Criteria:\n\n1. Age \\\u003C 16 years\n2. Patients who, in the opinion of the investigator, have co-morbidities that impair wound healing, such as:\n\n   1. Chronic inflammatory skin condition\n   2. Chronic liver failure\n   3. Chronic renal failure\n   4. Blood-borne viruses (Hep B, Hep C, HIV)\n   5. Peripheral vascular disease\n   6. Clinically significant anaemia\n   7. Uncontrolled diabetes\n3. Need for use of the same harvest site (re-cropping)\n4. History of radiation therapy to proposed donor site\n5. Chronic use of medications known to impair wound healing\n6. Chronic use of opioids or neuropathic pain agents\n7. Suspected cellulitis, osteomyelitis or septicaemia\n8. Patients undergoing haemodialysis\n9. Patients requiring spinal\u002Fregional block\n10. Patients on current anti-coagulant therapy\n11. Unable or unwilling to provide informed consent\n12. Unable or unwilling to comply with the study follow-up schedule, and procedures\n13. Simultaneously participating in another investigational drug or device study (patient must have completed the follow-up phase for the primary endpoint of any previous study at least 30 days prior to enrolment in this study)\n14. Allergy or hypersensitivity to materials that are porcine-based\n15. Cultural or religious objection to the use of pig or porcine products\n16. Known intolerance\u002Fallergy to standard wound care products\n17. Presence of a local infection at the donor site and\u002For systemic infection","16 Years",{"count":19,"type":20},[23],"The purpose of this study is to demonstrate the safety and performance of Oasis extracellular matrix (ECM) when used as a treatment for donor site wounds in the United Kingdom. Oasis ECM is commercially available for the treatment of partial and full-thickness skin wounds, including chronic wounds, wounds from trauma, and wounds that occur during surgery, such as donor site wounds. The ability of the Oasis ECM to promote the healing of donor site wounds will be evaluated in this study.\n\nAbout 40 patients (20 in each arm) over 16 years old will be involved in this study at one center in the United Kingdom.",[241,26,242,186],"Surgical Wound","Wounds and Injuries",[244],"Donor Site Wound","2024-12-12",{"date":247,"type":32},"2024-12-17",{"date":249,"type":32},"2020-11-01",{"date":251,"type":20},"2025-12",{"name":253,"class":66},"Cook Biotech Incorporated",{"id":255,"slug":256,"hasResults":11,"nctId":257,"briefTitle":258,"officialTitle":259,"acronym":4,"eligibilityCriteria":260,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":261,"targetDuration":4,"studyType":21,"phases":263,"briefSummary":264,"conditions":265,"keywords":267,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":271,"lastUpdatePostDateStruct":272,"startDateStruct":274,"completionDateStruct":276,"leadSponsor":278,"locationsCount":39},"100202543","pico-above-incisions-after-vascular-surgery-100202543","NCT01913132","PICO Above Incisions After Vascular Surgery","PICO Versus Standard Dressing on Groin Incisions After Vascular Surgery - a Prospective Randomized Trial (INVIPS Trial)","Inclusion Criteria:\n\n* Patients 18 years of age and above\n* Elective vascular surgery\n* Inguinal incision (transverse or longitudinal)\n* Capable of understanding the study information and giving written informed consent\n\nExclusion Criteria:\n\n* Emergency surgery\n* Ongoing infection in inguinal area",{"count":262,"type":20},644,[23],"The wound infection rate in the groin after vascular surgery has been denoted to be high since the wound surveillance register started in 2005. The current wound infection rate based on a validation study was 22.9% (24\u002F105 patients with groin incision(s) between 1 March to 30 June in 2012). This randomized controlled trial aims to evaluate if negative pressure wound therapy on closed inguinal incisions (INPWT) after vascular surgical procedures can reduce the risk for surgical site infections and other wound complications.",[26,266],"Infection",[268,269,270],"Negative pressure wound therapy","Vascular Surgery","Inguinal incisions","2024-11-26",{"date":273,"type":32},"2024-11-29",{"date":275,"type":32},"2013-11",{"date":277,"type":20},"2026-12",{"name":279,"class":38},"Stefan Acosta",{"id":281,"slug":282,"hasResults":11,"nctId":283,"briefTitle":284,"officialTitle":285,"acronym":4,"eligibilityCriteria":286,"healthyVolunteers":47,"sex":16,"minAge":287,"maxAge":288,"enrollmentInfo":289,"targetDuration":4,"studyType":21,"phases":291,"briefSummary":293,"conditions":294,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":296,"lastUpdatePostDateStruct":297,"startDateStruct":299,"completionDateStruct":301,"leadSponsor":303,"locationsCount":39},"100526762","phase-2-comparing-the-effect-of-sisparc-microneedle-patch-versus-sisparcsilr4a-microneedle-patch-on-post-surgical-scars-100526762","NCT06138964","Comparing the Effect of siSPARC Microneedle Patch Versus siSPARC+siLR4A Microneedle Patch on Post-surgical Scars","Randomized Intra-individually Controlled Double-blinded Trial Comparing Effect of Small Interfering RNA Against SPARC (siSPARC) Microneedle Patch Versus Small Interfering RNA Against SPARC and IL4-RA (siSPARC + siLR4A) Microneedle Patch on Appearance of Post-surgical Scars","Inclusion Criteria:\n\n* Adult\n* Age 21-75\n* 2 weeks (+\u002F- 7 days) after surgical operation with incision into the dermis\n* Post-stitch removal when stitches were applied\n* Wound closure\u002Funion achieved\n\nExclusion Criteria:\n\n* Pregnant or lactating participant\n* Participants with wound infection\n* Participants assessed to be uncooperative or unable to self-administer the interventions\n* Participants with known contact allergy to ingredients in the patch formulation (comprising hyaluronic acid, siRNA and glue) and\u002For isopropyl alcohol\n* Participants who are unable to personally consent (for e.g., cognitively impaired)","21 Years","75 Years",{"count":290,"type":20},50,[292],"PHASE2","This randomized, double-blind controlled study aims to compare the effect on appearance of post- surgical scars between daily application of siSPARC microneedle patch versus siSPARC + siLR4A microneedle patches. These are patches comprising short microneedles embedded with hydrolysed RNA (siRNAs).",[295,186,26],"Keloid","2024-06-20",{"date":298,"type":32},"2024-06-24",{"date":300,"type":32},"2023-11-14",{"date":302,"type":20},"2024-11-14",{"name":304,"class":305},"National Skin Centre","NETWORK"]